Mastocytosis is a rare heterogeneous disease with an incidence of five cases per million. In adults, it usually occurs in the form of systemic mastocytosis (SM). According to the World Health Organisation, 30% of patients with SM develop an associated clonal haematological non-mast cell lineage disease (SM-AHNMD) that determines overall prognosis, while the prognostic relevance of SM in these cases remains unclear. Unfortunately, successful treatment of the AHNMD hardly ever seems to include a lasting remission of SM. Thus, there is an ongoing discussion about the existence of a graft-versus-mast-cell (GvMC) effect after allo-SCT. Even concerning the special entity of SM-AHNMD there are controversial opinions. 1, 2 In cases where a putative GvMC effect is described, long-lasting complete remissions are rarely seen. 1, 3 Therefore, we report the rare case of one patient with SM and AML who achieved a CR of AML immediately after SCT. Interestingly, an at least very good stabilizing partial or maybe even CR of SM occurred with a delay of 3 years. Remission criteria are clearly defined for AML, but not for SM-especially not for SM-AHNMD. We used the criteria established for aggressive SM by Valent et al. 4 as most applicable. SM was diagnosed in this male patient at the age of 47 years, after the appearance of mediator-release symptoms, such as flushing, gastrointestinal symptoms and even anaphylaxis. Tryptase, a diagnostic marker in mastocytosis, was significantly increased. A 70% infiltration of the BM with D816V c-kit mutation-positive mast cells led to consecutive pancytopenia. Multiple para-aortic lymph nodes were enlarged up to 12 mm. Hepatosplenomegaly with impaired blood coagulation due to decreased liver function was detected. The liver was palpable four fingerbreadths below the costal arch, and the spleen measured 6 Â 9 Â 16 cm sonographically. Even a histologically verified perirenal manifestation with reduced kidney function because of a space-consuming infiltration of the whole retroperitoneum was diagnosed. The patient first received histamine receptor 1/2 antagonists and corticosteroids, then imatinib and cladribine, but both treatments were without response.
Six years after diagnosis of SM, the patient developed AML without molecular or cytogenetic abnormalities. After double induction therapy with two courses of high-dose Ara-C and mitoxanthrone analogous to the protocol of the German AML Cooperative Group, the patient remained aplastic and SM persisted unchanged. Because of planned SCT no consolidation therapy followed. SCT with cells from a matched unrelated donor was performed after a myeloablative conditioning with treosulfan 14 g/m 2 once daily from day À 6 to À 4 (total dose 42 g/m 2 ) and fludarabine 30 mg/m 2 once daily from day À 6 to À 2 (total dose 150 mg/m 2 ). CsA and methotrexate were used for prophylaxis of acute GvHD. De novo extensive chronic mucocutaneous GvHD developed, which made the use of donor lymphocytes impossible. Ongoing CR with complete donor chimerism was reached for the AML immediately after transplantation.
In contrast to AML, remission of SM was much delayed, and different manifestations responded at different time points. The mediator-release symptoms that frequently appeared before transplantation were not observed again during conditioning therapy or after SCT. Since day þ 23 there were no histological signs of mastocytosis in the BM, and the D816V c-kit mutation could not be detected in peripheral blood or BM any more. Three months after transplantation, liver function normalised despite initially persisting hepatosplenomegaly. Computer tomography showed no enlarged lymph nodes, but a nearly unchanged perirenal manifestation. Three years after SCT, hepatosplenomegaly was also regressive. The liver was palpable two fingerbreadths, under the costal arch, and the spleen measured 4 Â 8 Â 11 cm. The perirenal manifestation was reduced by approximately 90% to a residual finding without being space-consuming. This delayed response of the extramedullary manifestations is reminiscent of the poor response to GvHD of extramedullary lesions in other haematological diseases. 5 Tryptase has continually declined since SCT as shown in Figure 1 .
In this special case, there seems to be a GvMC effect that acts continuously over months and finally leads to a very good partial or even CR after years. The follow-up time in previously published cases without response of SM to SCT was possibly not long enough to detect a benefit of a GvMC effect. 2 The only residual findings of SM in our patient are slightly elevated tryptase levels, hepatosplenomegaly without liver dysfunction and a residual perirenal signal in computer tomography. The elevated tryptase levels maybe also explained by evidence that patients with GvHD tend to have elevated tryptase levels. 6 The remaining slight hepatosplenomegaly could be due to permanent medication intake or iron overload. The considerably reduced perirenal finding could represent inactive connective tissue, as it is seen after treatment in other diseases like lymphomas. The validity of positron emission tomography for restaging of mastocytosis and to examine tissue activity is controversially discussed. 7, 8 It is further worth mentioning again that our patient did not show a recurrence of mediator release symptoms in contrast to other reports. 1 So, there is a great benefit of SCT for both, leukaemia and mastocytosis.
SM seems to decline with increasing GvHD. At the time of this report, the patient still had an extended mucocutaneous GvHD requiring the combination of the three immunosuppressive drugs CsA, prednisone and mycophenolate mofetil. As immunosuppressive drugs may reduce mastocytosis 9 one could argue that immunosuppression, but not GvHD, leads to the decrease of SM. But although immunosuppressive treatment could not be stopped, reduction has been possible. CsA was reduced from 100 to 25 mg/day and prednisone from 30 to 15 mg/day. Only mycophenolate mofetil is applied unmodified with 2 g/day. The decline of SM even after reduction of immunosuppression is an indication against regression of SM through immunosuppressive drugs.
The intensity of chemotherapy for primary therapy or conditioning therapy before SCT in patients with SM-AHNMD is determined by the malignant haematological disease and does not seem to have a superior role for overcoming SM that is known to show limited response to chemotherapy. 10 In this case SM also remained unchanged after induction chemotherapy. Remission stabilized years after transplantation, when an influence of chemotherapy could be excluded. However, both non-myeloablative and myeloablative conditioning regimens can result in SM persistence, as reported in other cases. 1, 2 In conclusion, this case provides evidence for the existence of a relevant GvMC effect with remission-inducing potential. The special feature is that stable remission of SM is reached years after transplantation, so a long follow-up period is necessary to evaluate the presence of a remission-inducing GvMC effect. Therefore, it is possible that the follow-up period is not long enough in reports that deny such an effect.
